PacBio Bets on RS II to Drive Future Orders as Q1 Revenues Slide 44 Percent | GenomeWeb

This story was originally published on April 25.

Pacific Biosciences is betting on its recently launched PacBio RS II system as well as increased usage by current customers to drive future revenues, officials said last week during a conference call discussing the firm's first-quarter earnings.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.